Thông tin thuốc gốc
Chỉ định và Liều dùng
Hypertensive crisis
Adult: 10-20 mg as a single dose, a further dose of 10-20 mg may be given after 3 hours, if necessary.
Renal Impairment
CrCl (mL/min) Dosage
41-65 Dose reduction or longer intervals between doses may be required.
Chống chỉ định
Phaeochromocytoma, heart failure unrelated to hypertension. Concomitant use or within 2 weeks of MAOIs. Severe renal impairment (CrCl 10-40 mL/min).
Thận trọng
Patient with coronary or cerebral artery disease, asthma, history of gastrointestinal ulceration, Parkinson’s disease with associated autonomic neuropathy. Moderate renal impairment (CrCl 41-65 mL/min). Pregnancy (not recommended during the 1st trimester or within 2 weeks before labour) and lactation. Withdraw treatment few days prior to surgery.
Phản ứng phụ
Significant: CNS effect (e.g. dizziness, blurred vision, drowsiness), latent heart failure (prolonged use), fever.
Cardiac disorders: Bradycardia, sick-sinus syndrome.
Gastrointestinal disorders: Nausea, diarrhoea, vomiting, dry mouth, gaseous distension.
General disorders and administration site conditions: Lethargy, oedema, tiredness.
Investigations: Increased BUN levels (in patients with latent or manifest renal failure).
Nervous system disorders: Headache, paraesthesia.
Renal and urinary disorders: Uraemia (in patients with latent or manifest renal failure).
Reproductive system and breast disorders: Ejaculation disturbances, erectile dysfunction (including priapism).
Respiratory, thoracic and mediastinal disorders: Rarely, asthma.
Vascular disorders: Postural hypotension, exacerbation of intermittent claudication.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, drowsiness, or blurred vision, if affected, do not drive or operate machinery.
Monitor blood pressure and renal function.
Quá liều
Symptoms: Postural hypotension causing syncope, sinus bradycardia, tiredness, dizziness, tachycardia, blurred vision, muscle weakness, nausea, vomiting, severe diarrhoea, and oliguria. Management: Symptomatic treatment. In case of postural hypotension, keep the patient in a recumbent position or institute fluid and electrolyte replacement; if necessary, may administer pressor agents. Administer atropine for sinus bradycardia. Treat diarrhoea with an anticholinergic agent.
Tương tác
May lead to sinus bradycardia when given concurrently with antiarrhythmic agents and digitalis. Antihypertensive effect may be increased by reserpine, methyldopa, vasodilators (e.g. minoxidil), calcium channel blockers, β-blockers, ACE inhibitors. Antihypertensive effect may be decreased by TCAs, phenothiazine derivatives, chlorpromazine, oral contraceptives. May increase hypersensitivity to adrenaline, amphetamines, or other sympathomimetic agents.
Potentially Fatal: May lead to release of large quantities of catecholamines causing hypertensive crisis when given to patient previously treated with MAOIs.
Food Interaction
Alcohol may enhance the antihypertensive effect of guanethidine.
Tác dụng
Description: Guanethidine is a peripheral sympathetic blocking agent. It lowers blood pressure by depleting and inhibiting reformation of noradrenaline in postganglionic nerve endings, but it does not prevent the secretion of catecholamines by the adrenal medulla.
Onset: Fall in blood pressure: Within 30 minutes.
Distribution: Enters breast milk (small amounts).
Metabolism: Partially metabolised in the liver.
Excretion: Via urine as metabolites and unchanged drug. Terminal half-life: Approx 5 days.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3518, Guanethidine. Accessed Mar. 25, 2021.

Phân loại MIMS
Phân loại ATC
C02CC02 - guanethidine ; Belongs to the class of guanidine derivatives, peripherally-acting antiadrenergic agents. Used in the treatment of hypertension.
Anon. Guanethidine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 09/03/2021.

Buckingham R (ed). Guanethidine Monosulfate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 09/03/2021.

Ismelin 10 mg/mL Ampoules (Amdipharm UK Limited). MHRA. Accessed 09/03/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Guanethidine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in